(Q39068190)

English

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

scientific article published on 20 December 2016

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

cystic fibrosis

0 references

1 reference

based on heuristic

inferred from title

Christopher H Goss

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Michael W Konstan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Edward F McKone

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Richard B Moss

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Gautham Marigowda

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Simon Tian

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

David Waltz

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Xiaohong Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Barry Lubarsky

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jaime Rubin

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Stefanie J Millar

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

David J Pasta

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Nicole Mayer-Hamblett

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Wayne Morgan

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Gregory S Sawicki

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

21 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

107-118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying treatments that halt progression of pulmonary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Spirometric reference values from a sample of the general U.S. population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulmonary function between 6 and 18 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Matching using estimated propensity scores: relating theory to practice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of deterioration of lung function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A contemporary survival analysis of individuals with cystic fibrosis: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Children and young adults with CF in the USA have better lung function compared with the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930427-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(16)30427-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28011037%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39068190&oldid=2171562377"